Homologous and heterologous prime boost vaccinations with distinct variants of Plasmodium vivax circumsporozoite protein (CSP) protects mice against transgenic PB/PV sporozoite challenge
Vaccine development against Plasmodium vivax malaria lags behind that for Plasmodium falciparum. To narrow this gap, we administered recombinant antigens based on P. vivax circumsporozoite protein (CSP) to mice.
Main Authors: | Freitas, E, Camargo, T, Gimenez, A, Lima, L, Caramico, K, Francoso, K, Bruna-Romero, O, Ertl, H, Nussenzweig, R, Nussenzweig, V, Rodrigues, M, Reyes-Sandoval, A, Soares, I |
---|---|
Formato: | Conference item |
Publicado em: |
American Society of Tropical Medicine and Hygiene
2017
|
Registos relacionados
-
Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge
Por: de Camargo, T, et al.
Publicado em: (2018) -
Exit of Plasmodium sporozoites from oocysts is an active process that involves the circumsporozoite protein.
Por: Qian Wang, et al.
Publicado em: (2005-09-01) -
Vaccine containing the three allelic variants of the Plasmodium vivax circumsporozoite antigen induces protection in mice after challenge with a transgenic rodent Malaria parasite..
Por: Gimenez, A, et al.
Publicado em: (2017) -
Development of a sporozoite malaria vaccine
Por: Victor Nussenzweig, et al.
Publicado em: (1986-01-01) -
Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite
Por: Alba Marina Gimenez, et al.
Publicado em: (2017-10-01)